Subscribe on Apple Podcasts, Google Podcasts, Overcast, Spotify, Stitcher, Vimeo, YouTube.
When analyzing the life cycle of any health care product, a key component to consider is how much the product will cost and who will pay for it. What unique challenges do direct access tests (DATs) pose when it comes to reimbursement and related compliance requirements?
On the second episode of our four-part series on direct access laboratory testing, Bob Hearn and Megan Robertson, attorneys at Epstein Becker Green, and Dr. Joel Brill, a strategic consultant at EBG Advisors, Inc., discuss coverage and reimbursement for DATs, as well as the related compliance factors that labs, product developers, and investors in the diagnostic testing industry should be aware of.
Stay tuned for upcoming episodes and guests in our special series on direct access laboratory testing.
About the Diagnosing Health Care Podcast
What health care and life sciences decision-makers need to lead, comply, and compete. The health care industry is full of high-stakes legal, policy, and regulatory obstacles. And significant opportunities for those prepared to act on them. Diagnosing Health Care® delivers the intelligence executives, general counsel, and administrators need to navigate both. Part of the Epstein Becker Green Insights Network.
Email Notifications
Follow Us
Never miss an episode! Subscribe to Diagnosing Health Care on your preferred platform:
Also on Audible | Deezer | Goodpods | iHeartRadio | PlayerFM | Pocket Casts | YouTube Music
People
- Member of the Firm
- Member of the Firm
Services
- Academic and Clinical Research
- Corporate Compliance Program Development, Implementation, and Effectiveness
- Drug and Medical Device Distribution
- FDA Inspections and Enforcement
- Health Care
- Health Care and Life Sciences Investigations and Enforcement
- Health Care and Life Sciences Investor Services
- Industry Research and Clinical Trials
- Life Sciences
- Life Sciences Due Diligence
- Product Marketing and Compliance
- Regulatory Strategy, Product Development, and Product Approvals